DYN NASDAQ
Dyne Therapeutics, Inc.
1W: -27.0%
1M: -30.4%
3M: +1.4%
YTD: -1.6%
1Y: +37.1%
3Y: +54.7%
5Y: +9.0%
$18.21
-0.21 (-1.14%)
Weekly Expected Move ±9.1%
$15
$17
$18
$20
$22
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.4B
52W Range11.92-27.305
Volume3,774,338
Avg Volume2,247,942
Beta1.08
Dividend—
Analyst Ratings
Company Info
CEOJohn G. Cox
Employees289
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-17
Websitedyne-tx.com
1560 Trapelo Road
Waltham, MA 02451
US
Waltham, MA 02451
US
781 786 8230
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Latest News
Dyne extends slide as J.P. Morgan downgrades on Novartis setback
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Biggest stock movers Tuesday: ZIM, NVS, and more
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Friedl-Naderer Johan | S-Sale | 185 | $18.88 | 2026-09-08 |
| Kerr Douglas | S-Sale | 1,290 | $18.88 | 2026-09-08 |
| Cox John | S-Sale | 5,658 | $18.88 | 2026-09-08 |
| Friedl-Naderer Johan | S-Sale | 900 | $24.35 | 2026-09-04 |
| Kerr Douglas | S-Sale | 3,745 | $24.35 | 2026-09-04 |